Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.

Published in: American journal of hematology (2024)

A triplet regimen is usually needed at relapse, with the choice of regimen varying with each successive relapse. Chimeric antigen receptor T (CAR-T) cell therapy and bispecific antibodies are additional options.

Keyphrases

cell therapy
multiple myeloma
free survival
stem cells
mesenchymal stem cells
energy transfer
bone marrow